InterCure CEO Alex Rabinovitch Purchases Over 420,000 Shares of Company Stock in The Open Market

Oct 12, 2021
PDF Version

NEW YORK, TORONTO and HERZLIYA, Israel, Oct. 12, 2021 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) today announced that CEO Alexander Rabinovitch purchased, throughout the month of September 2021, a total of 423,501 shares of the Company’s common stock.

Mr. Rabinovitch purchased the shares by buying 423,501 shares in the open market at an average price of USD$7.03 per share (CAD $8.95 or NIS 22.69). The shares were purchased partially on the NASDAQ and in part on the Tel Aviv Stock Exchange, for a total investment in the Company of USD$2,975,730 (CAD $3,790,238 per share or NIS 9,608,631).

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: http://www.intercure.co.

To be added to InterCure’s email distribution list, please email InterCure@kcsa.com with “InterCure” in the subject.

Contact:

InterCure Ltd.
Amos Cohen, Chief Financial Officer
amos@canndoc-pharma.com

KCSA Strategic Communications
Investor and Media Relations
InterCure@kcsa.com